Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
BMS Not Yet Recruiting Study icon

Not Yet Recruiting

Trial ID CA236-0001  |   NCT06697197

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

Warning icon
Sorry, this study is not yet accepting participants.
Please bookmark this page to check back at a later date.  You may also click the “Check if you qualify” button and answer a few questions about your health to find out if you might be a match to another study.

Summary

  • Phase 1/Phase 2
  • Male and Female Gender icon
  • 18+
    Age Range
  • 6
    Locations
  • BMS Not Yet Recruiting Study icon
    Not Yet Recruiting

Overview

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
:
  • All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and have received, be refractory to, ineligible for, intolerant of, or refused existing therapy(ies) known to provide clinical benefit for the condition of the participant.
    1. Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, inclusive, at the time of signing the ICF.
      1. Participants in Part 1A may have NSCLC, SCCHN, MSS-CRC, gastric/GEJ adenocarcinoma, urothelial carcinoma, PDAC, melanoma or breast cancer (TNBC and ER+HER2-).
        1. Participants in Part 1B1 and 2B1 must have NSCLC and, if known, should have documented status for EGFR, KRAS, ALK, ROS1, RET, NTRK, MET exon 14 skipping mutations, and BRAF V600E.Participants must have received platinum-based chemotherapy and anti-PD-(L)1 therapy, if eligible and available.
          1. Participants in Parts 1B2, 2B2, and 1C must have cutaneous, acral, mucosal, or unknown primary melanoma. Participants with uveal/ocular melanoma are excluded. Participants must be melanoma 2L+.
            1. Participants in Part 1B3 must have advanced or metastatic MSS-CRC.
              1. Participants in Part 2A may have advanced solid tumors (advanced, unresectable, or metastatic NSCLC, advanced, unresectable, hormone resistant ER+HER2-breast cancer or pancreatic adenocarcinoma [PDAC]) based on emerging data.
                1. Participants in Part 2B3 must have advanced or metastatic MSS-CRC.
                  1. For all participants in Part 1C cohort, a tumor sample from a ("fresh") biopsy [core biopsy (at least 4 passages recommended), punch biopsy, excisional biopsy or surgical specimen] must be obtained (obtained within 1 month of the start of the Screening, if there are tumor sites that can be biopsied with acceptable clinical risk).

                    Exclusion Criteria

                    Exclusion Criteria Icon
                    :
                    • History of life threatening immune mediated toxicity related to prior T-cell agonist or checkpoint inhibitor therapy, except those that are unlikely to re-occur with standard countermeasures.
                      1. Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator.
                        Additional Information *
                        • Other protocol-defined Inclusion/Exclusion criteria apply.

                          Treatment Options

                          Study Arms

                          ASSIGNED INTERVENTION

                          Study Arms

                          Experimental: Part 1A

                          ASSIGNED INTERVENTION
                          • Drug: BMS-986482

                          Study Arms

                          Experimental: Part 1B1

                          ASSIGNED INTERVENTION
                          • Drug: BMS-986482, Nivolumab and rHuPH20

                          Study Arms

                          Experimental: Part 1B2

                          ASSIGNED INTERVENTION
                          • Drug: BMS-986482, Nivolumab/relatlimab/rHuPH20

                          Study Arms

                          Experimental: Part 1B3

                          ASSIGNED INTERVENTION
                          • Drug: BMS-986482, Bevacizumab

                          Study Arms

                          Experimental: Part 1C

                          ASSIGNED INTERVENTION
                          • Drug: BMS-986482

                          Study Arms

                          Experimental: Part 2A

                          ASSIGNED INTERVENTION
                          • Drug: BMS-986482

                          Study Arms

                          Experimental: Part 2B1

                          ASSIGNED INTERVENTION
                          • Drug: BMS-986482, Nivolumab and rHuPH20

                          Study Arms

                          Experimental: Part 2B2

                          ASSIGNED INTERVENTION
                          • Drug: BMS-986482, Nivolumab/relatlimab/rHuPH20

                          Study Arms

                          Experimental: Part 2B3

                          ASSIGNED INTERVENTION
                          • Drug: BMS-986482, Bevacizumab
                          Please check back later for a recruiting site or find another trial by clicking 'Check if you qualify'
                          Check if you qualify
                          Answer some questions about Your health to see if you may match to this trial
                          Match to a Trial
                          If you are a match, click on the study to see the list of study site locations.
                          Select a Study Site Location
                          Select a study site location that is convenient for you
                          Register
                          Provide your contact details for the study site to connect with you.

                          Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you